Authors: Jun Tang, et al.

作者：Jun Tang 等

Published in: Anesthesiology, 2002

发表期刊：《麻醉学》，2002年

Objective:

The study aimed to evaluate the effectiveness of parecoxib, an intravenous COX-2 inhibitor, in reducing postoperative opioid requirements and enhancing the quality of pain control in patients undergoing surgery.

研究目的：

评估帕瑞昔布（静脉环氧合酶-2抑制剂）在减少术后阿片类药物需求量及提高疼痛控制质量方面的效果。

Methodology:

Study Design: Double-blind, placebo-controlled trial
Participants: Patients scheduled for various types of surgeries
Interventions: Patients were randomized to receive either parecoxib or a placebo.
Measurements: Postoperative opioid consumption, pain intensity scores, and adverse effects were recorded and analyzed.

方法：

研究设计：双盲、安慰剂对照试验
参与者：计划进行各种类型手术的患者
干预措施：患者被随机分配接受帕瑞昔布或安慰剂。
测量：记录并分析术后阿片类药物消耗量、疼痛强度评分及不良反应。

Key Findings:

Reduction in Opioid Use: Patients receiving parecoxib required significantly less postoperative opioids compared to the placebo group.
Improved Pain Control: The quality of pain control was better in the parecoxib group, as evidenced by lower pain intensity scores.
Safety and Tolerability: Parecoxib was well tolerated with a safety profile similar to the placebo.

主要发现：

减少阿片类药物使用：接受帕瑞昔布的患者术后所需阿片类药物显著少于安慰剂组。
疼痛控制改善：帕瑞昔布组的疼痛控制质量更好，疼痛强度评分较低。
安全性和耐受性：帕瑞昔布耐受性良好，其安全性与安慰剂相似。

Conclusion:

Parecoxib is an effective analgesic that reduces the need for opioids and improves pain management postoperatively without increasing adverse effects.

结论：

帕瑞昔布是一种有效的镇痛药，可减少术后阿片类药物的使用并改善疼痛管理，同时不增加不良反应。

相关化合物及其CAS号

1. **Parecoxib (帕瑞昔布)**
   - **CAS Number:** 198470-85-8
2. **Celecoxib (塞来昔布)**
   - **CAS Number:** 169590-42-5
3. **Rofecoxib (罗非昔布)**
   - **CAS Number:** 162011-90-7
4. **Ketorolac (酮咯酸)**
   - **CAS Number:** 74103-07-4